Polycythemia Vera

• JAK2 V617F Mutation and Signal Transduction Abnormality: The pathognomonic JAK2 V617F point mutation (located on chromosome 9q34) occurs in the pseudokinase domain of the JAK2 protein, resulting in constitutive activation of JAK2 tyrosine kinase independent of cytokine binding. This mutant JAK2 protein activates downstream signaling cascades including the STAT3/STAT5 and PI3K/AKT pathways, leading to ligand-independent proliferation of hematopoietic progenitors in response to normal EPO concentrations that would not normally trigger proliferation. The mutation arises in a multipotent hematopoietic stem cell and confers a proliferative advantage, resulting in clonal expansion of the affected cell line. Over time, the JAK2 V617F clone outcompetes normal hematopoietic stem cells, eventually dominating the bone marrow compartment and producing the characteristic hematologic picture. Approximately 50% of patients are homozygous for the JAK2 V617F mutation (suggesting acquisition of a second mutational hit in the malignant clone during disease progression), while the remainder are heterozygous; homozygosity is associated with higher hemoglobin levels and greater thrombotic risk.

• EPO-Independent Erythropoiesis and Red Cell Mass Expansion: In normal hematopoiesis, EPO production is tightly regulated by renal oxygen sensing, and erythroid progenitors respond to EPO stimulation via JAK2-STAT5 signaling. In PV, JAK2 V617F-expressing progenitors become hypersensitive to EPO and can proliferate at subtherapeutic EPO concentrations; additionally, these cells acquire mutations that further enhance EPO-independent growth potential. As red cell mass expands dramatically (often to 150% of normal or higher), negative feedback mechanisms normally suppress EPO production, resulting in inappropriately low serum EPO levels (<2 mIU/mL) in the face of elevated hemoglobin. This represents a cardinal pathophysiologic finding: the simultaneous presence of elevated red cell mass and suppressed EPO, which is essentially pathognomonic for PV and distinguishes it from secondary polycythemia. The progressive expansion of red cell mass occurs across all three hematopoietic lineages (erythroid, myeloid, megakaryocytic), though erythrocytosis predominates clinically.

• Bone Marrow Hypercellularity and Trilineage Proliferation: Histologic examination of the bone marrow reveals panmyelosis—hypercellular marrow with proliferation of all three myeloid lineages (erythroid, myeloid, and megakaryocytic precursors). The trilineage proliferation distinguishes PV from other myeloproliferative neoplasms; patients typically manifest elevated hemoglobin, elevated white blood cell count (often 12,000-25,000/μL but may be higher), and thrombocytosis (often 400,000-600,000/μL). Megakaryocytes are increased in number and often display abnormal morphology, particularly clustering around blood vessels. The marrow becomes increasingly fibrotic over time as megakaryocytes and monocytes elaborate transforming growth factor-beta (TGF-β) and other fibrogenic cytokines. This secondary myelofibrosis (termed "spent phase" PV or post-PV myelofibrosis) develops in approximately 5-15% of patients over 15-20 years and represents acquisition of additional somatic mutations conferring enhanced fibrogenic potential.

• Thrombotic Pathophysiology and Vascular Complications: PV carries marked thrombotic risk due to multiple mechanisms: (1) severe erythrocytosis increases blood viscosity exponentially, particularly at the microvascular level, impairing blood flow and promoting stasis and thrombosis, especially when hematocrit exceeds 50-52%; (2) platelet dysfunction in PV results from abnormal platelet production, leading to both thrombotic (despite high counts, platelet function is paradoxically impaired) and hemorrhagic manifestations; (3) endothelial dysfunction from JAK2 V617F expression in endothelial cells and increased oxidative stress; (4) leukocyte activation with increased leukocyte-endothelium interactions and tissue factor expression. The combination of these factors results in a distinctly elevated risk for arterial thrombosis (myocardial infarction, ischemic stroke, peripheral arterial occlusion) exceeding that seen in other myeloproliferative neoplasms. Microvascular occlusive episodes—manifested as erythromelalgia (painful erythema of extremities), thrombotic stroke, or splenic infarction—are particularly characteristic of PV and directly related to blood viscosity and platelet dysfunction.

• Hemorrhagic Manifestations and Acquired von Willebrand Syndrome: Paradoxically, despite marked thrombocytosis and thrombotic tendency, PV patients suffer increased bleeding risk due to acquired von Willebrand syndrome (vWS)—high platelet counts shear off high-molecular-weight multimers of von Willebrand factor, reducing platelet adhesion and causing a mild coagulopathy. This explains spontaneous bleeding (gastrointestinal bleeding, epistaxis, mucosal hemorrhage) despite elevated platelet counts and contributes to the characteristic "wet" bleeding (rather than "dry") seen with severe thrombocytosis in PV. The bleeding risk is worsened by antiplatelet or anticoagulant therapy, making management challenging.

• Secondary Malignant Transformation and Genomic Instability: Accumulation of additional somatic mutations over time (in addition to JAK2 V617F) drives evolution toward secondary myelofibrosis or acute myeloid leukemia (AML), with the latter occurring in 5-10% of patients at 15 years of follow-up. Common secondary mutations include TP53, ASXL1, IDH1/IDH2, and others that promote myeloid transformation. Notably, certain cytotoxic therapies (particularly chlorambucil, pipobroman, or radioactive phosphorus P-32) substantially increase AML transformation risk and are now avoided in favor of JAK inhibitors. The natural history of PV thus evolves from the initial myeloproliferative phase through possible secondary myelofibrosis to potential leukemic transformation.

• JAK2 V617F Mutation (Primary Cause): This somatic point mutation in JAK2 is present in >95% of PV cases and is the defining molecular lesion of the disease. The mutation results in constitutive kinase activation and is acquired somatically in a hematopoietic stem cell; it is neither inherited nor present in germline DNA. The mutation confers a profound proliferative and survival advantage to hematopoietic progenitors, explaining clonal dominance. While presence of JAK2 V617F is necessary for PV diagnosis, it is not sufficient—other mutations or genetic factors modulate the phenotype and severity. Testing for JAK2 V617F is the cornerstone of PV diagnosis and is present at diagnosis in the vast majority of patients.

• CALR and MPL Mutations in JAK2-Negative Cases: Approximately 3-5% of clinically typical PV patients lack the JAK2 V617F mutation ("JAK2-negative PV"). The vast majority of these cases harbor mutations in CALR (calreticulin gene) or MPL (thrombopoietin receptor gene). CALR mutations activate thrombopoietin signaling and JAK-STAT pathways through an alternative mechanism, while MPL mutations directly affect the thrombopoietin receptor. JAK2-negative, CALR- or MPL-mutated cases typically present with higher platelet counts and lower hemoglobin levels compared to JAK2-positive PV, and may have slightly different natural history. Identification of these mutations in JAK2-negative patients is important for confirming the diagnosis and occasionally for prognostic stratification.

• Age and Older Demographic: PV predominantly affects older adults, with median diagnosis age of 60-65 years. The advanced age at presentation likely reflects the time required for clonal evolution and additional mutations to develop beyond the initial JAK2 V617F event. Age itself is a risk factor for thrombotic complications and influences treatment decisions (older patients may tolerate JAK inhibition better due to reduced thrombotic burden from lower hemoglobin targets).

• Absence of Secondary Causes (Exclusion Criterion): Unlike secondary polycythemia (from hypoxia, renal disease, erythropoietin-secreting tumors, or EPO administration), PV is definitionally a primary process arising from intrinsic clonal abnormality rather than an appropriate response to pathophysiologic stimulus. The presence of low/inappropriately normal serum EPO in the setting of elevated red cell mass specifically excludes secondary causes and points toward PV or other primary polycythemias (acquired or congenital).

• Erythromelalgia: This is a pathognomonic microvascular occlusive phenomenon presenting as episodic burning pain, erythema, and warmth in the extremities (particularly the feet and lower legs), often triggered by exposure to heat or exertion. Episodes may last hours to days and are exquisitely responsive to aspirin (pain relief within 30-60 minutes), which is a diagnostic and therapeutic clue. Erythromelalgia reflects platelet-mediated microvascular thrombosis and is highly specific for PV among the myeloproliferative neoplasms. Severe untreated erythromelalgia can lead to skin ulceration and tissue necrosis.

• Thrombotic Events: Arterial thrombotic events are the leading cause of morbidity and mortality in PV. Patients present with myocardial infarction, ischemic stroke, transient ischemic attacks, or peripheral arterial thrombosis. These events occur in 10-25% of patients at diagnosis or during follow-up and reflect the combined effects of elevated blood viscosity, platelet dysfunction, and endothelial abnormality. Notably, thrombotic risk extends to splenic infarction (causing acute left upper quadrant pain) and Budd-Chiari syndrome (hepatic vein thrombosis presenting with portal hypertension, ascites, and hepatomegaly)—splanchnic vein thrombosis is particularly common in PV relative to other myeloproliferative neoplasms.

• Hemorrhagic Manifestations: Despite elevated platelet counts, bleeding is common and paradoxical. Spontaneous gastrointestinal bleeding is the most frequent bleeding complication, presenting with hematemesis, melena, or positive fecal occult blood. Epistaxis and mucosal bleeding also occur. Bleeding is worsened by severe thrombocytosis and acquired von Willebrand syndrome, and is paradoxically exacerbated by cytoreductive therapy that raises hemoglobin. The concurrent thrombotic and hemorrhagic tendency ("both clotting and bleeding") is a clinical hallmark and causes management dilemmas.

• Constitutional and Metabolic Symptoms: Patients commonly report fatigue, weight loss, night sweats, and low-grade fever—constitutional symptoms reflecting the myeloproliferative state and cytokine production. Pruritus is a distinctive symptom present in up to 50% of patients, typically triggered by contact with water (aquagenic pruritus) or occurring spontaneously; it is markedly uncomfortable and often refractory to standard antihistamines. The pruritus is believed to result from increased histamine production by neoplastic mast cells and basophils. Hyperuricemia and gout occur from increased cell turnover and urate production, and patients may present with acute gouty arthritis.

• Symptoms of Hyperviscosity: Elevated blood viscosity produces headache, dizziness, vertigo, visual disturbances (blurred vision, amaurosis fugax), and cognitive slowing. Some patients describe a "molasses-like" quality to their blood or complain of a sensation of fullness in the head. These symptoms correlate with hematocrit and improve rapidly with phlebotomy or cytoreductive therapy.

• Splenomegaly: Physical examination reveals splenomegaly in 40-50% of cases due to extramedullary hematopoiesis and splenic myeloproliferation. Occasionally, splenic infarction superimposed on an enlarged spleen causes acute left upper quadrant pain and elevation of lactate dehydrogenase (LDH). Mild hepatomegaly may also be present.

• Plethora and Ruddy Complexion: Patients with significant erythrocytosis display a characteristic ruddy, plethoric appearance with dark redness of the face and mucous membranes, reflecting the elevated hemoglobin and hematocrit. Conjunctival suffusion (engorgement of conjunctival vessels) may be noted on examination.

• Absence of Lymphadenopathy: In contrast to lymphoproliferative malignancies, lymphadenopathy is absent in uncomplicated PV, which helps exclude other diagnoses.

Clinical Diagnosis and WHO Criteria

Major Criteria

1. 1.Elevated red cell mass (defined as hemoglobin >16.5 g/dL in men or >16 g/dL in women, or hematocrit >49% in men or >48% in women) OR elevated hemoglobin/hematocrit on repeated measurements
2. 2.Bone marrow biopsy showing panmyelosis with proliferation of all three lineages (erythroid, myeloid, megakaryocytic) without significant dysplasia or fibrosis (early/prefibrotic stage) OR hypercelluarity with trilineage proliferation and prominent megakaryocytes (overtly fibrotic variant)
3. 3.Presence of JAK2 V617F or other clonal mutation (CALR or MPL) OR lack of secondary causes of erythrocytosis

Minor Criterion

• Subnormal serum erythropoietin (EPO) level (<2 mIU/mL) with elevated red cell mass

• Hemoglobin/Hematocrit as Diagnostic Parameter: Elevated hemoglobin and hematocrit are the initial findings prompting further workup. Hemoglobin >16.5 g/dL in men or >16 g/dL in women, or hematocrit >49% in men or >48% in women meets the threshold for major criterion. These cutoffs account for gender differences in normal hemoglobin. Note that the WHO criteria emphasize absolute red cell mass elevation rather than hemoglobin alone (since some patients are hemoconcentrated), so direct measurement of red cell mass using chromium-51 radioisotope method may be performed if hemoglobin is borderline, though this is rarely necessary in modern practice.

• JAK2 V617F Molecular Testing: JAK2 V617F mutation testing by PCR or allele-specific PCR is the definitive diagnostic test, positive in >95% of PV cases. High allelic burden (>50% of alleles mutated) suggests homozygosity and is associated with higher hemoglobin/hematocrit and increased thrombotic risk. Quantitative JAK2 testing (determining the percentage of JAK2 V617F-positive cells) may inform prognosis but does not direct initial management. All PV patients without JAK2 V617F should be tested for CALR and MPL mutations; approximately 3-5% will be positive.

• Serum Erythropoietin Level: Serum EPO <2 mIU/mL in the

Immediate stabilization

• Symptomatic hyperviscosity (stupor, visual loss, focal deficit) or acute thrombosis is an emergency: perform urgent therapeutic phlebotomy with isovolemic crystalloid replacement; erythrocytapheresis is an option where available. Acute thrombosis is treated with standard anticoagulation for the site involved (e.g., splanchnic/Budd-Chiari thrombosis warrants prompt systemic anticoagulation and hepatology involvement).

First-line therapy in every patient (NCCN Guidelines for Myeloproliferative Neoplasms; European LeukemiaNet)

• Phlebotomy: the cornerstone. Target hematocrit <45%, the threshold validated by the CYTO-PV trial, which showed fewer cardiovascular deaths and major thromboses versus a more permissive target. Iron deficiency is the intended consequence — do not supplement iron, as this restores erythropoiesis.
• Low-dose aspirin: 81 mg daily unless contraindicated; blocks platelet-mediated microvascular occlusion and abolishes erythromelalgia.
• Cardiovascular risk factor control: smoking cessation, blood pressure, lipids, glycemia — thrombosis, not marrow failure, kills these patients.

Cytoreduction (add for high-risk disease: age ≥60 or prior thrombosis; also for progressive splenomegaly, symptomatic disease, extreme thrombocytosis, or intolerance of phlebotomy)

• Hydroxyurea (antimetabolite/ribonucleotide reductase inhibitor): usual first-line cytoreductive agent.
• Interferons: ropeginterferon alfa-2b-njft is FDA-approved for PV and peginterferon alfa-2a is used off-label; preferred in younger patients and the agent of choice in pregnancy, where hydroxyurea is contraindicated.

Second-line / escalation

• Ruxolitinib (JAK1/2 inhibitor): for hydroxyurea resistance or intolerance, especially with symptomatic splenomegaly or refractory aquagenic pruritus.
• Busulfan: reserved for elderly patients given leukemogenic concern.
• Allogeneic stem cell transplant: the only curative option, reserved for post-PV myelofibrosis or leukemic transformation.

Supportive/contraindicated

• Allopurinol for hyperuricemia/gout; antihistamines, SSRIs, or narrowband UVB for pruritus.
• Avoid chlorambucil, pipobroman, and radioactive phosphorus-32 (leukemogenic). Hold or defer aspirin when acquired von Willebrand syndrome is documented by low ristocetin cofactor activity with extreme thrombocytosis — cytoreduce first. Splenectomy is generally avoided.

Disease-related — vascular (leading cause of death)

• Arterial thrombosis (MI, ischemic stroke, TIA, limb ischemia): viscosity, platelet and leukocyte activation, endothelial dysfunction. Emergency.
• Splanchnic vein thrombosis / Budd-Chiari syndrome: hepatic venous outflow obstruction presenting with ascites, tender hepatomegaly, and rapid-onset portal hypertension. Emergency — and a presentation in which counts may be deceptively normal because of hemodilution and hypersplenism.
• Splenic infarction: acute left upper quadrant pain, pleuritic referred left shoulder pain, rising LDH in a patient with known splenomegaly.
• Hyperviscosity syndrome: headache, blurred vision, amaurosis fugax, obtundation — signals need for urgent phlebotomy.

Disease-related — hemorrhagic and metabolic

• Acquired von Willebrand syndrome: extreme thrombocytosis adsorbs high-molecular-weight vWF multimers; mucocutaneous or GI bleeding despite a high platelet count, with reduced ristocetin cofactor activity. Aspirin worsens it.
• Hyperuricemia and gout / uric acid nephrolithiasis: high cell turnover.
• Iron deficiency: from serial phlebotomy — microcytosis and high RDW with a high red cell count; expected, not corrected.

Disease progression

• Post-PV myelofibrosis ("spent phase"): TGF-β–driven marrow fibrosis; falling hemoglobin with new transfusion dependence, worsening splenomegaly, leukoerythroblastic smear with teardrop cells (dacrocytes).
• Acute myeloid leukemia: cytopenias with circulating blasts; poor prognosis.

Treatment-related

• Hydroxyurea: myelosuppression, macrocytosis (a marker of adherence), painful oral and lower-leg ulcers, nonmelanoma skin cancers.
• Interferons: flu-like syndrome, cytopenias, depression/suicidality, autoimmune thyroiditis.
• Ruxolitinib: anemia and thrombocytopenia, herpes zoster reactivation, nonmelanoma skin cancer, and a cytokine rebound/withdrawal syndrome if stopped abruptly — taper.
• Alkylators and P-32: increased leukemic transformation, which is why they are avoided.

• The diagnostic dyad: elevated hematocrit plus a low serum EPO is PV until proven otherwise; the confirmatory test is JAK2 V617F. High or normal EPO points to secondary erythrocytosis instead.
• Single best next step for unexplained erythrocytosis: serum EPO and JAK2 V617F testing — not a bone marrow biopsy first, and not a red cell mass study, which is rarely needed in modern practice.
• Aquagenic pruritus (itching after a hot shower) and erythromelalgia (burning red feet relieved within an hour by aspirin) are the two buzzwords examiners lean on; erythromelalgia responding to aspirin is essentially a PV giveaway.
• The one association tested: Budd-Chiari syndrome or unexplained splanchnic vein thrombosis in a young patient — test for JAK2 V617F even if the CBC looks normal, since GI bleeding, iron deficiency, and hypersplenism can mask the erythrocytosis.
• Two numbers worth memorizing: phlebotomize to hematocrit <45% and give aspirin 81 mg daily; add hydroxyurea only if age ≥60 or prior thrombosis (NCCN Guidelines for Myeloproliferative Neoplasms).
• Microcytic erythrocytosis is PV with phlebotomy-induced iron deficiency — the trap is to give iron or to diagnose thalassemia trait. Do neither; iron repletion regenerates the red cell mass.
• Distractors to avoid: secondary polycythemia (COPD, sleep apnea, high altitude, right-to-left shunt, testosterone use, renal cell or hepatocellular carcinoma) has high EPO and no splenomegaly; Gaisböck syndrome (relative polycythemia) has a contracted plasma volume with normal red cell mass. Neither has pruritus, splenomegaly, thrombocytosis, or leukocytosis.
• Bleeding despite thrombocytosis = acquired von Willebrand syndrome; check ristocetin cofactor activity and cytoreduce rather than reflexively adding more antiplatelet therapy.
• Hydroxyurea is teratogenic — use interferon in pregnancy.